Trial Profile

An observational evaluation of prescribing of fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist (ICS/LABA): fluticasone propionate / formoterol (FP/FOR) and adverse events in routine primary care at 18-months and 36-months post launch

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 27 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Formoterol/fluticasone propionate (Primary) ; Beclometasone/formoterol; Budesonide/formoterol; Salmeterol/fluticasone propionate
Indications Asthma; Chronic obstructive pulmonary disease
Focus Adverse reactions

27 Nov 2019 New source identified and integrated (EUPAS12330: The European Union electronic Register of Post-Authorisation Studies Register)
27 Nov 2019 New trial record
20 Nov 2019 Results assessing adverse outcomes and prescribing practices for FP/FORM and other FDC ICS/LABA therapies in a real-life clinical setting over 36 months were published in the Drugs

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com